Technical challenges in procuring, isolating, and deriving stem cells exist, as do the ethical controversies around the use of stem cells. This webinar brings together a panel of experts to discuss hope, the hype, and what we can realistically expect to see going forward.
Stem cells have the potential to play an important role in drug discovery and regenerative medicine. Induced pluripotent stem cells (iPSCs), particularly those derived from patients, are already being used to better understand and model complex diseases. They offer a more physiologically relevant system to decipher genetic effects and to test drug candidates in early discovery. Innovative technologies and strategies are also being employed to assess the role of iPSCs and embryonic stem (ES) cells in regenerative medicine and cell therapy.
Although much progress has been made on both fronts—in drug discovery and in stem-cell therapy—challenges still persist. Technical challenges in procuring, isolating, and deriving stem cells exist, as do the ethical controversies around the use of stem cells. Differentiating stem cells into the desired tissue type, growing them to model specific conditions for drug discovery or for understanding the repair function of stem cells, and overcoming immunological rejection following...
Meet the Speakers:
Dr. Clive Svendsen
Director
Cedars-Sinai Regenerative Medicine Institute, Los Angeles, CA
Dr. Kevin Eggan
Associate Professor, Department of Stem Cell and Regenerative Biology
Principal Investigator, Harvard Stem Cell Institute
Harvard University
Dr. Florian Merkle
Postdoctoral Fellow
Eggan Lab
Dr. Birgitt Schuele
Associate Professor and Director, Gene Discovery and Stem Cell Modeling
The Parkinson’s Institute and Clinical Center, Sunnyvale, CA
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
